Table 1

Characteristics of patients with ascites at the time of listing for liver transplantation subdivided according to the presence or absence of NSBB

PrematchPropensity risk score matched
NSBB
(n:159)
Non-NSBB
(n:163)
p ValueNSBB
(n:104)
Non-NSBB
(n:104)
p ValueEffect size
Age (years)55.0 (8.6)53.2 (10.6)0.10754.7 (9.1)53.4 (10.2)0.3750.134
Male gender97 (61.0)112 (68.7)0.14774 (71.2)70 (67.3)0.6590.128
Blood group
 O70 (44.6)69 (42.9)47 (46.1)48 (47.1)0.020
 A66 (42.0)66 (41.0)40 (39.1)39 (38.2)0.018
 B/AB21 (13.4)26 (16.1)0.78315 (14.7)15 (14.7)0.8600.000
Body mass index (kg/m2)27.2 (4.9)28.3 (6.1)0.06727.2 (4.8)27.5 (5.1)0.7200.061
Diagnosis*
 Alcohol60 (37.7)62 (38.0)0.95642 (40.4)41 (39.4)1.0000.020
 Hepatitis C30 (18.9)33 (20.2)0.75524 (23.1)21 (20.2)0.7430.070
 Cholestatic31 (19.5)36 (22.1)0.56718 (17.3)22 (21.2)0.5970.099
 Non-alcoholic fatty liver disease22 (13.8)20 (12.3)0.67610 (9.6)13 (12.5)0.6640.093
 Hepatocellular carcinoma15 (9.4)23 (14.1)0.19311 (10.6)12 (11.5)1.0000.029
Diabetes mellitus38 (23.9)37 (22.7)0.79924 (23.1)23 (22.1)1.0000.024
Blood parameters at listing
 Bilirubin (μmol/L)51 (30–98)55 (33–116)0.16453 (31–107)54 (32–114)0.7220.043
 Albumin (g/L)31 (6)31 (6)0.80330 (6)31 (6)0.1380.167
 INR1.4 (1.2–1.7)1.4 (1.2–1.7)0.4531.5 (1.2–1.8)1.4 (1.2–1.6)0.3970.091
 Creatinine (μmol/L)89 (27)88 (26)0.68191 (27)91 (26)0.9020.000
 eGFR (mL/min/1.73 m2)75 (61–98)78 (64–107)0.26674 (62–97)76 (61–99)0.9300.028
 Sodium (mmol/L)136 (6)134 (5)0.016135 (5)135 (5)0.8140.000
MELD score16 (5)17 (5)0.16817 (5)17 (5)0.8100.000
UKELD score56 (6)57 (5)0.01457 (6)57 (6)0.9600.000
Previous variceal haemorrhage64 (40.3)40 (24.5)0.00329 (27.9)29 (27.9)1.0000.000
Refractory ascites56 (35.2)61 (37.4)0.68139 (37.5)37 (35.6)0.8850.039
Hepatorenal syndrome (type 2)7 (4.4)8 (4.9)0.8305 (4.8)6 (5.8)1.0000.045
Prophylactic antibiotics37 (23.3)43 (26.4)0.51821 (20.1)23 (22.1)0.8710.049
  • p Value in bold indicates statistical significance.

  • Values expressed as mean (SD), median (IQR) and number (per cent) where appropriate.

  • *Some patients had more than one aetiology of liver disease.

  • eGFR, estimated glomerular filtration rate; INR, international normalised ratio; MELD, model for end-stage liver disease; NSBB, non-selective β-blockers; UKELD, UK Score for Patients with End-Stage Liver Disease.